Topotecan Now Available for HIV, PML Research


The drug topotecan, being developed as a cancer treatment by
SmithKline Beecham, will be made available to certain outside
researchers interested in studying its possible use in
treating HIV or PML (progressive multifocal
leukoencephalopathy). Prospective researchers must have their
pre-clinical or clinical plans approved by SmithKline
Beecham, and must sign an agreement that they will NOT file
for a use patent on the drug.

Topotecan was discussed several times in AIDS TREATMENT NEWS
in 1994. Researchers at Dana-Farber Cancer Institute showed
that it has a strong anti-HIV effect; however, SmithKline
Beecham is not interested in developing it for AIDS, and
believes it would be too toxic as an AIDS or PML treatment.
SmithKline Beecham is testing chemical derivatives, however,
to learn whether the toxicity and anti-HIV effect can be
separated.

Researchers interested in more information should call Sharyn
Arnold at 215/751-7074, or send a fax directed to her at
215/751-7655.

ACT UP/New York has taken the lead in efforts to revive AIDS-
related research on this drug.